Cinacalcet Tablet, Film Coated
Product Images NDC 0904-7502

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Cinacalcet (NDC 0904-7502). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30mg* Carton Label (0692252e 4cc6 4f16 8a54 Aeacd59c3143 00)

Cinacalcet 30 mg film-coated tablets packaging label from Major Pharmaceuticals. The label shows the product name, strength, dosage form, and a unit dose quantity of 30 tablets (3 x 10). It includes storage instructions, cautionary statements, and distributor information for Major Pharmaceuticals, Indianapolis, Indiana.*

FDA Label Image

Cinacalcet-structure (61399d7c Ee88 4df1 B3b3 B4995e787a53 01)

Chemical structure of cinacalcet hydrochloride, showing the molecular arrangement including aromatic rings, an amine group, methyl substitution, and trifluoromethyl group.*

FDA Label Image

Figure 1 (61399d7c Ee88 4df1 B3b3 B4995e787a53 02)

A line graph comparing iPTH (pg/mL) levels over 26 weeks between Cinacalcet and placebo groups. The Cinacalcet group (red line) shows a decreasing trend in iPTH levels, while the placebo group (black dashed line) maintains relatively stable levels. Error bars indicate variability at each time point.*

FDA Label Image

Figure 2 (61399d7c Ee88 4df1 B3b3 B4995e787a53 03)

A line graph comparing calcium-phosphorus product levels (Ca x P mg/dL) over 26 weeks between two groups: one receiving Cinacalcet and the other receiving a placebo. The Cinacalcet group, shown with a red line, demonstrates a marked decrease in Ca x P levels from week 0 to 10, followed by a relatively stable trend. The placebo group, shown with a black dashed line, maintains higher and more stable Ca x P levels throughout the study period.*

FDA Label Image

Figure-3 (61399d7c Ee88 4df1 B3b3 B4995e787a53 04)

A line graph depicting serum calcium levels (mg/dL) over weeks during treatment phases labeled as Titration and Maintenance. The x-axis shows weeks from baseline (B) through week 80, and the y-axis shows calcium levels from 8 to 16 mg/dL. Data points indicate mean calcium levels with error bars, and the number of patients at each time point is noted below the x-axis.*

FDA Label Image

Figure-4 (61399d7c Ee88 4df1 B3b3 B4995e787a53 05)

A line graph illustrating calcium levels (mg/dL) over weeks, divided into titration and maintenance phases. The x-axis represents time in weeks, and the y-axis shows calcium concentration. Data points with error bars indicate changes in calcium levels during treatment, with sample sizes noted for intractable pHPT patients at the bottom.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.